Edmund Tse

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Vincent Leroy, Peter Angus, Jean–Pierre Bronowicki et al. · Hepatology · 2016 · 279 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection

Fred Poordad, William Sievert, Lindsay Mollison et al. · JAMA · 2015 · 95 citations

Medicine, Infectious Diseases, Pharmacology +17

Applying New Diagnostic Criteria for Acute Kidney Injury To Facilitate Early Identification of Nephrotoxicity in Vancomycin-Treated Patients

Emi Minejima, Joyce Choi, Paul M. Beringer et al. · Antimicrobial Agents and Chemotherapy · 2011 · 94 citations

Medicine, Nephrology, Pharmacotherapy +17

Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy

Stuart K. Roberts, Ricky Lim, Simone I. Strasser et al. · Clinical Gastroenterology and Hepatology · 2017 · 53 citations

Medicine, Pharmacology, Pharmacotherapy +11

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

Amanda Nicoll, Stuart K. Roberts, Ricky Lim et al. · Alimentary Pharmacology & Therapeutics · 2019 · 38 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14